Outlook Therapeutics Price Target Maintained With a $12.00/Share by Guggenheim

Dow JonesJan 17 22:26 · Ratings

HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target

BenzingaJan 17 20:31 · Ratings

Outlook Therapeutics Analyst Ratings

BenzingaJan 17 20:29 · Ratings

Positive Outlook for Outlook Therapeutics Driven by Promising ONS-5010 Data and Strategic Market Positioning

TipRanksJan 17 19:16

Sector Update: Health Care Stocks Rise Late Afternoon

MT NewswiresJan 17 04:54

Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD

MT NewswiresJan 17 01:44